ReferenceID 1482

Carnosol inhibits inflammasome activation by directly targeting HSP90 to treat inflammasome-mediated diseases

Cell Death Dis

Aberrant activation of inflammasomes, a group of protein complexes, is pathogenic in a variety of metabolic and inflammation-related diseases. Here, we report that carnosol inhibits NLRP3 inflammasome activation by direc

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final reference record.

Reference Id
1482
Evidence Id
18072
Core Evidence Id
18072
Source Reference Id
2978
Herb2 Reference Id
HBREF003775
Subject Paper Key
HBIN019759_32312957
Pubmed Id
32312957
Doi
10.1038/s41419-020-2460-x
Paper Title
Carnosol inhibits inflammasome activation by directly targeting HSP90 to treat inflammasome-mediated diseases
Paper Abstract
Aberrant activation of inflammasomes, a group of protein complexes, is pathogenic in a variety of metabolic and inflammation-related diseases. Here, we report that carnosol inhibits NLRP3 inflammasome activation by directly targeting heat-shock protein 90 (HSP90), which is essential for NLRP3 inflammasome activity, thereby treating inflammasome-mediated diseases. Our data demonstrate that carnosol inhibits NLRP3 inflammasome activation in primary mouse bone marrow-derived macrophages (BMDMs), THP-1 cells and human peripheral blood mononuclear cells (hPBMCs). Mechanistically, carnosol inhibits inflammasome activation by binding to HSP90 and then inhibiting its ATPase activity. In vivo, our results show that carnosol has remarkable therapeutic effects in mouse models of NLRP3 inflammasome-mediated diseases, including endotoxemia and nonalcoholic steatohepatitis (NASH). Our data also suggest that intraperitoneal administration of carnosol (120 mg/kg) once daily for two weeks is well tolerated in mice. Thus, our study reveals the inhibitory effect of carnosol on inflammasome activation and demonstrates that carnosol is a safe and effective candidate for the treatment of inflammasome-mediated diseases.
Journal
Cell Death Dis
Publish Year
2020
Experiment Subject
mouse; human; thp-1 cells
Experiment Type
Cell Experiment
Phenotype Related
Inflammasome-mediated Diseases; Nonalcoholic Steatohepatitis; Nlrp3 Inflammasome-mediated Diseases; Endotoxemia; Inflammation-related Diseases
Paper Title Cn
Paper Title En
Carnosol inhibits inflammasome activation by directly targeting HSP90 to treat inflammasome-mediated diseases
Bilingual Status
semi_complete